NEUP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neuphoria Therapeutics Inc (NEUP) is not a strong buy at this time for a beginner investor with a long-term strategy. The lack of positive financial performance, absence of significant news or catalysts, and neutral trading trends suggest limited growth potential in the near term. The technical indicators do not provide a compelling entry point, and there are no proprietary trading signals to support a buy decision.
The MACD histogram is positive and expanding, indicating mild bullish momentum. RSI is neutral at 64.846, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support and resistance levels are Pivot: 4.467, R1: 4.792, and S1: 4.142, with the pre-market price at 4.54 sitting between the pivot and R1.
NULL identified. No recent news or significant trading trends from hedge funds or insiders. Technical indicators show mild bullish momentum but lack strong confirmation.
The company's financial performance in Q2 2026 is extremely poor, with revenue, gross margin, and EPS all dropping significantly year-over-year. Net income also declined sharply. No recent congress trading data or influential figure activity to suggest confidence in the stock.
In Q2 2026, revenue dropped to 0 (-100.00% YoY), net income dropped to 1864092 (-195.92% YoY), EPS dropped to 0.41 (-133.33% YoY), and gross margin dropped to 0 (-100.00% YoY). This reflects a significant decline in the company's financial health.
No analyst rating or price target changes available for review.
